MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2024.102212

Медицинская библиотека · Clinical genitourinary cancer · 2024

Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.

Kobayashi Keita, Matsumoto Hiroaki, Sakano Shigeru, Yamamoto Mitsutaka, Tsuchida Masahiro, Tei Yasuhide, Nagao Kazuhiro, Oba Kazuo, Kitahara Seiji, Yano Seiji, Yoshihiro Satoru, Yamamoto Yoshiaki, Ohmi Chietaka, Komatsu Hirotaka, Misumi Taku, Akao Jumpei, Shiraishi Koji

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

In cases of metastatic and unresectable urothelial carcinoma with no disease progression after 4 cycles of chemotherapy, including platinum agents, treatment options include continuation of chemotherapy or switching to maintenance therapy with avelumab. This study compared the treatment outcomes of avelumab maintenance therapy with those of pembrolizumab in urothelial carcinoma using propensity score matching.

PATIENTS AND

METHODS

Between January 2017 and December 2022, 243 patients with metastatic and unresectable urothelial carcinoma were treated with either avelumab or pembrolizumab at the Yamaguchi University Hospital and its affiliated institutions. We retrospectively compared the oncological outcomes and adverse events by aligning patient characteristics and treatment backgrounds using propensity score matching.

RESULTS

The analysis compared 36 cases receiving avelumab maintenance therapy after chemotherapy to 49 cases where patients, after receiving 4 courses of chemotherapy including platinum-based agents without disease progression, were subsequently administered pembrolizumab as a second-line treatment following disease progression. Using propensity score matching, 27 cases from each group were selected for comparison. From the initiation of prechemotherapy to disease progression on immune checkpoint inhibitors, the median progression-free survival was 20.7 and 23.3 months in the avelumab and pembrolizumab groups, respectively, with no statistically significant difference observed (P = .358). However, avelumab tended to have a lower rate of high-dose glucocorticoid treatment compared to pembrolizumab.

CONCLUSION

Progression-free survival was similar for avelumab maintenance therapy and the sequence of continued chemotherapy followed by pembrolizumab after no disease progression at four chemotherapy courses. Avelumab may require less high-dose glucocorticoid treatment, potentially enhancing safety.

Для цитирования: Kobayashi Keita, Matsumoto Hiroaki, Sakano Shigeru, Yamamoto Mitsutaka, Tsuchida Masahiro, Tei Yasuhide, Nagao Kazuhiro, Oba Kazuo, Kitahara Seiji, Yano Seiji, Yoshihiro Satoru, Yamamoto Yoshiaki, Ohmi Chietaka, Komatsu Hirotaka, Misumi Taku, Akao Jumpei, Shiraishi Koji. Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.. Clinical genitourinary cancer. 2024. DOI: 10.1016/j.clgc.2024.102212.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.